Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · Real-Time Price · USD

10.71

+0.14 (1.32%)

Aug 13, 2025, 4:00 PM - Market closed

Lyell Immunopharma Employees

Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.

Employees

300

Change (1Y)

76

Growth (1Y)

33.93%

Revenue / Employee

$200

Profits / Employee

-$1,104,657

Market Cap

167.40M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	300	76	33.93%
Dec 31, 2023	224	-50	-18.25%
Dec 31, 2022	274	55	25.11%
Dec 31, 2021	219	29	15.26%
Dec 31, 2020	190	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

LYEL News

1 day ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 - GlobeNewsWire
20 days ago - Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewsWire
23 days ago - Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement - Seeking Alpha
7 weeks ago - Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire
2 months ago - Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma - GlobeNewsWire
2 months ago - Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewsWire
2 months ago - Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewsWire
3 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewsWire